Observational studyRheumatology international2025
Clinical profile and outcome of patients with ANCA-associated vasculitis with special reference to vasculitis damage index: a longitudinal observational study.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) is the most commonly encountered primary small-vessel vasculitis, with an annual incidence of 20 per million. The data on AAV from the Southeast Asian ethnicity is scarce. The present longitudinal observational study was undertaken to determine the clinical profile and outcomes in fifty-eight consecutive patients of AAV attending the Department of Rheumatology in a tertiary care centre in India. The majority (39, 67.2%) were females with a mean (± SD) age at baseline of 39.2 (± 15.2) years. Granulomatosis with polyangiitis (GPA) was the most common phenotype, accounting for 40 cases (69.0%). The patients were followed up for a mean (± SD) duration of 35.4 (± 31.4) months. The most commonly affected organ domains were the respiratory (46, 79.3%), musculoskeletal (41, 70.7%), and the renal domains (38, 65.5%). In our cohort, a significantly higher number of patients exhibited ophthalmological involvement (31, 53.4%). There were a total of 22 relapse events among 11 patients, representing a relapse rate of 19%. The case-fatality rate was 10.6%. The majority received treatment with intravenous methylprednisolone (46; 79.3%) and intravenous cyclophosphamide (42; 72.4%) during the induction phase, while rituximab (28; 48.3%) was the preferred first-line maintenance agent. BVAS of 22.5 was related to VDI ≥ 5 (p = 0.000). The mean (± SD) Vasculitis Damage Index (VDI) accrued was 2.41 (± 1.97). The most common treatment-related damage included osteoporosis (40%), diabetes (40%), and cataract (13%), whereas the common disease-related damage included diastolic hypertension (58%) and impaired lung function (27%). Higher Birmingham Vasculitis Activity Score (BVAS) at presentation (OR: 1.25, 95% CI 1.031-1.522) and relapse of scleritis (OR: 35.27, 95% CI 1.152 -1000.000) were found to be independent predictors of high VDI ≥ 5. This is the first study from Eastern India that has looked into the clinical profile of AAV and its damage index.
Indexed as
Identifiers
41329207What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.